Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $21.86 Average Target Price from Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have earned a consensus recommendation of “Hold” from the nine brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $21.3333.

A number of analysts recently weighed in on KROS shares. Wall Street Zen lowered shares of Keros Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. TD Cowen raised shares of Keros Therapeutics to a “hold” rating in a report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Keros Therapeutics in a report on Monday, December 29th. Zacks Research lowered shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, March 5th.

Institutional Trading of Keros Therapeutics

Institutional investors have recently bought and sold shares of the business. Financial Management Professionals Inc. acquired a new stake in Keros Therapeutics during the 4th quarter worth $29,000. Caitong International Asset Management Co. Ltd grew its holdings in Keros Therapeutics by 254.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after acquiring an additional 1,166 shares during the period. Farther Finance Advisors LLC acquired a new stake in Keros Therapeutics during the 3rd quarter worth $47,000. Tower Research Capital LLC TRC grew its holdings in Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after acquiring an additional 1,888 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Keros Therapeutics during the 3rd quarter worth $103,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Price Performance

Shares of Keros Therapeutics stock opened at $11.15 on Tuesday. The firm has a market cap of $219.88 million, a P/E ratio of 6.13 and a beta of 0.98. The firm has a 50 day simple moving average of $13.48 and a 200 day simple moving average of $16.31. Keros Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, March 4th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.37). The company had revenue of $0.39 million during the quarter, compared to analyst estimates of $3.66 million. Keros Therapeutics had a net margin of 35.65% and a return on equity of 14.25%. The business’s revenue for the quarter was down 87.2% on a year-over-year basis. During the same period in the prior year, the business earned ($1.14) EPS. On average, sell-side analysts expect that Keros Therapeutics will post -4.74 EPS for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.